According to the company, Mr Kaiser brings more than three decades of executive-level leadership to the board at a time when RBC Life Sciences is focusing on aggressive domestic and international expansion.
Mr Kaiser is chairman and CEO of CLST Holdings, the public company remaining from the 2007 sale of Cellstar. As Cellstar’s chairman and CEO, Mr Kaiser raised the company’s market capitalization by securing new funding sources, developing new product lines and entering new markets.
John Price, president of RBC Life Sciences, said: “Robert has an impressive entrepreneurial background and strategic experience in profit and revenue expansion and shareholder development that will serve the company as it positions itself moving forward. Robert’s expertise will be invaluable as we redouble growth efforts within the US and abroad.”